- The collaboration with Aarhus University's neurosurgical team will
evaluate IRRAflow during the treatment of Intraventricular
Hemorrhage (IVH) and assessment of brain compliance
STOCKHOLM, April 6, 2021 /PRNewswire/ -- IRRAS, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced a strategic collaboration with Aarhus University Hospital
(AAUH) in Aarhus, Denmark, one of
Scandinavia's leading medical institutions.
Dr. Anders Korshøj, Associate Professor of Neurosurgery at
Aarhus University Hospital, will lead the collaboration that will
unite specialists from the hospital's neurocritical care team and
data analytics experts from The Aarhus University Center for
Digitalization, Big Data and Data Analytics. The collaboration will
focus initially upon the use of the company's
IRRAflow system to treat patients suffering from
intraventricular hemorrhage (IVH). The facility's use of
IRRAflow in the treatment of IVH will be prospectively
compared to the use of traditional drainage treatments in the
pending ACTIVE clinical study. Beyond this study, other clinical
and product development projects are also being planned.
Aarhus University Hospital is an 854-bed academic teaching
hospital that, in 2020, was named Denmark's best hospital for the 13th
consecutive year by healthcare newspaper, Dagens Medicin. The
institution was also recently ranked as the 11th best hospital in
the world by the American publication, Newsweek. The hospital's
Departments of Neurosurgery and Neurointensive Care are leaders
throughout all of Scandinavia as the departments are responsible
for both general and highly specialized procedures for patients
across all of Denmark.
IRRAflow is the world's first "irrigating
intracranial drain" and its unique mechanism of action addresses
the complications associated with the current methods of managing
intracranial fluid by using a dual-lumen catheter that combines
automated irrigation, controlled drainage, and continuous
monitoring of intracranial pressure (ICP), all within one
system.
"It is my belief that the system's combination of automated
irrigation and controlled drainage should contribute to better
long-term outcomes for these critically ill patients," said Dr.
Korshøj. "Furthermore, we believe that the system's ability to
measure pressure immediately after fluid movement is uniquely
capable of measuring real-time intracranial compliance, and I am
excited to partner with IRRAS to explore these hypotheses in
greater detail."
Traditional treatment options for IVH patients generally utilize
an external ventricular drainage (EVD) system, which is a passive
approach that relies solely on gravity to facilitate
drainage. Although an EVD is currently the most common
treatment option for intracranial bleeding or elevated ICP, the
technology is associated with several well-known complications such
as catheter blockage, infections, and incomplete drainage. All of
these complications can negatively impact patient outcome, which
can subsequently increase the length of time needed in the hospital
and the overall cost of care.
"This collaboration with Aarhus University Hospital represents
an important component of our launch strategy for IRRAflow,"
said Will Martin, President and
Chief Commercial Officer of IRRAS. "There is a compelling need in
markets around the globe for transformative technologies, such as
IRRAflow, to treat patients with intracranial bleeding, and
we believe that our collaboration with Aarhus University Hospital
to collect clinical data will advance the treatment of IVH and also
accelerate the product's awareness to a wider group of
neurocritical care specialists."
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker:
IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on April 6, 2021 at 08:30 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-collaboration-with-aarhus-university-hospital--scandinavian-leader-in-neurosurgery--,c3319855